The incidence of transient myocardial ischemia,
|
|
- Shanna Nash
- 5 years ago
- Views:
Transcription
1 AJH 1999;12:50S 55S Heart Rate and the Rate-Pressure Product as Determinants of Cardiovascular Risk in Patients With Hypertension William B. White Inability to supply oxygen to the myocardium when demand is high appears to be related to several cardiovascular events, including transient myocardial ischemia, acute myocardial infarction, and sudden death. Myocardial oxygen consumption is correlated with the rate-pressure product (heart rate systolic blood pressure) and this hemodynamic parameter has been shown to follow a circadian pattern similar to that observed with cardiovascular events. However, the clinical implications of this observation and the appropriate clinical interventions have not been studied. Therefore, the impact of the chronotherapeutic controlled-onset extended release delivery (COER-verapamil) on heart rate and the rate-pressure product was assessed and compared with that of nifedipine gastrointestinal therapeutic system (GITS), which is designed to provide a constant or homeostatic drug effect. A total of 557 hypertensive patients were enrolled in The incidence of transient myocardial ischemia, myocardial infarction (MI), nonfatal MI, and sudden death follows a circadian pattern, with peak time for onset during the first hour before and the 3 h after awakening. 1 3 Heart From the Section of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut. Dr. White is supported in part by the Patrick and Catherine Weldon Donaghue Medical Research Foundation, Hartford, Connecticut. Address correspondence and reprint requests to William B. White, MD, Chief, Section of Hypertension and Clinical Pharmacology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT the 51-center, randomized, double-blind prospective study. Twenty-four hour ambulatory blood pressure (BP) monitoring was performed at baseline, after 4 weeks of stable-dose therapy, and after 10 weeks of treatment; heart rate was assessed concomitantly. Heart rate, rate of rise (slope) of BP and heart rate, and the rate-pressure product were all reduced to a greater extent by COER-verapamil during the early morning hours compared with the nifedipine GITS treatment. Thus, COER-verapamil exerted a beneficial hemodynamic profile for the treatment of the increases in rate-pressure product typically observed in the early morning in patients with hypertension. Am J Hypertens 1999; 12:50S 55S 1999 American Journal of Hypertension, Ltd. KEY WORDS: Heart rate, systolic blood pressure, ratepressure product, chronotherapy, controlled-onset extended release delivery system. rate and systolic blood pressure (BP) follow a similar pattern, rising sharply between 6 and 9 am. 4 Further, these two hemodynamic parameters have been shown to increase significantly 1 min before the onset of silent ischemic events. 5 Epidemiologic data have also demonstrated a positive relationship between elevated resting heart rate and increased mortality. 6,7 In the Göteborg Primary Prevention Trial, investigators discovered that total mortality increased with rising resting heart rate, peaking when heart rate was 90 to 99 beats/min. 6 Data derived from a 26-year follow-up of men aged 35 to 84 years during the Framingham Study showed that men in the highest two quintiles of resting heart rate (80 to 87 and 88 beats/min, respectively) were at signifi by the American Journal of Hypertension, Ltd /99/$20.00 Published by Elsevier Science, Inc. PII S (98)
2 AJH FEBRUARY 1999 VOL. 12, NO. 2, PART 2 HR, BP, AND CARDIOVASCULAR RISK 51S FIGURE 1. Relationship between rate-pressure product and silent ischemic events in patients with silent coronary artery disease.*p.005 compared with 6 am baseline; *P.01 compared with 6 am baseline. Based on data from Deedwania and Nelson. 5 cantly increased risk for cardiovascular mortality in general and sudden death in particular. 7 In a recent metaanalysis of several relevant studies, Palatini and Julius 8 confirmed this association and also noted that individuals with elevated heart rates were more likely to develop hypertension than subjects with low rates. Myocardial oxygen consumption is the most important indicator of the load on the heart. 9 Major determinants of myocardial oxygen demand are left ventricular systolic pressure, radius, and mass, contractility, and heart rate. 10 Although myocardial oxygen consumption is difficult to measure directly, the rate-pressure product (heart rate systolic BP) is a strong correlate of myocardial oxygen consumption and is an easy parameter to measure in ambulatory patients. In both normotensive and hypertensive men with coronary artery disease, the occurrence of ischemic events in the early morning period has been shown to be closely related to increases in the rate-pressure product. 5 Further, many of these events were preceded by a nearly 20% increase in the rate-pressure product approximately 5 min before onset of ST-segment depression (Figure 1). These findings, in addition to the recognized circadian variation in cardiovascular events, suggest a role for a chronotherapeutic approach to treating hypertension and ischemic heart disease. Timing of a drug s effects to align with the intrinsic circadian variation of the illness may prevent cardiovascular events. EVALUATING EFFECTS OF CHRONOTHERAPY ON HEART RATE AND RATE-PRESSURE PRODUCT A recent study assessed the impact of chronotherapy on BP, heart rate, and rate-pressure product, particularly during the early morning hours, in patients with hypertension. 11 The study compared the effects of a controlled-onset extended release delivery system (COER-verapamil) with those of a homeostatic delivery system (nifedipine gastrointestinal therapeutic system [GITS]), which is designed to provide a constant drug effect. A total of 557 patients were randomized to receive either COER-verapamil (n 276) or nifedipine GITS (n 281). Patients were titrated for 180 mg to 480 mg every night for verapamil and 30 to 120 mg every morning for nifedipine based on office BP measurements ( 140/90 mm Hg). Among the patients who received drug treatment, 400 achieved normotensive office BP during the study (n 202 for COER-verapamil and n 189 for nifedipine GITS), although many patients required an intermediate or high dose to do so. 11 The primary variable for assessing efficacy was the change in early morning BP (the 4-h period defined as 1 h before to 3 h after awakening) from baseline after 4 weeks of taking a stable dose of COER-verapamil or nifedipine GITS. The two treatments were defined as clinically equivalent if the mean change from baseline between groups in early morning systolic BP was 5 mmhgand 3 mm Hg for diastolic BP. Other study efficacy measures included changes from baseline in the early morning (1 h before and 3 h after awakening), changes in heart rate, rate-pressure product, and the rate of rise (slope) of BP and heart rate. Additionally, changes from baseline in 24-h mean, awake, and sleep BP and heart rate were compared for the two treatment groups. Actual awake and sleep times have been determined to be preferable to arbitrary daytime and nighttime averages of ambulatory
3 52S WHITE AJH FEBRUARY 1999 VOL. 12, NO. 2, PART 2 FIGURE 2. Mean changes in early morning heart rate with COER-verapamil and nifedipine GITS after 4 weeks and at the end of the study (10 weeks). P.001 between treatment groups. Based on data from White et al. 11 BP and heart rate, 12 as they result in more accurate assessments of sleep BP, in particular. At 4 weeks after stabilization of drug dosing and at the end of 10 weeks of therapy, mean changes in early morning BP were clinically equivalent between the two treatment groups. The patients receiving nifedipine GITS did experience a clinically significantly greater reduction of nocturnal systolic BP (5.2 mm Hg greater among patients receiving the homeostatic therapy versus COER-verapamil; P.001). Changes in early morning heart rate from baseline differed significantly between the two groups (P.001). In patients who received nifedipine GITS, heart rate increased approximately 2 beats/min, compared with a decrease of about 4 beats/min in the COERverapamil patients (Figure 2). The mean changes in heart rate during awake periods versus sleep reflected a similar trend. Heart rate was increased among nifedipine GITS patients during the awake period, whereas it decreased significantly among those receiving COER-verapamil (P.001 between treatment groups) (Figure 3). Both drugs decreased the rate of rise in BP at 4 and 10 weeks of treatment. However, the rate of rise in heart rate during the early morning period was increased with nifedipine GITS treatment and was decreased significantly with COER-verapamil therapy (P.001). COER-verapamil exerted a significant effect on the rate-pressure product, especially in the early morning. At 4 weeks, the mean changes in rate-pressure product during the early morning period were mm Hg beats/min and mm Hg beats/min in the COER-verapamil and nifedipine GITS groups, respectively (P.0001). At the end of the study, COER-verapamil continued to demonstrate this effect, significantly more so than nifedipine GITS ( mm Hg beats/min versus mm Hg beats/min, respectively, P.0003). For all ambulatory monitoring parameters, COERverapamil demonstrated a greater slowing effect on heart rate than nifedipine GITS. The difference between the two groups was highest during the awake period at 4 and 10 weeks of therapy (8 and 9 beats/ min, respectively). During sleep, this difference was not as great (4 and 3 beats/min at 4 and 10 weeks of therapy, respectively). Mean reductions in 24-h ambulatory rate-pressure product at 4 weeks of stable dosing were greater among patients in the COER-verapamil group than in those in the nifedipine GITS group, predominantly over the 12-h period from 6 am to 6 pm (Figure 4). The most marked effect occurred between 6 am and 6 pm and was least evident between 10 pm and 4 am. The average reduction in the rate-pressure product obtained with COER-verapamil treatment approximated FIGURE 3. Mean changes in heart rate (awake v asleep) with COER-verapamil versus nifedipine GITS. P.001 between treatment groups. Based on data from White et al. 11
4 AJH FEBRUARY 1999 VOL. 12, NO. 2, PART 2 HR, BP, AND CARDIOVASCULAR RISK 53S FIGURE 4. Changes from baseline in 24-h rate-pressure product after administration of nifedipine GITS (given in the morning) or COER-verapamil (given at bedtime). Study was performed after 4 weeks of stable therapy. Error bars represent 1 SEM change. Adapted from White et al: Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising early morning blood pressure, heart rate, and the heart rate-blood pressure product. Am J Cardiol 1998;81: , with permission of Excerpta Medica Inc. 11 5% during sleep and was about 20% during the early morning period. In contrast, nifedipine GITS reduced the rate-pressure product about 5% to 7% throughout the dosing interval. Of the 281 patients in the nifedipine GITS group, 207 (74%) reported at least one adverse event during the study, compared with 188 (68%) among those in the COER-verapamil group (22% v 4%) (P NS). The nifedipine GITS group had significantly more peripheral edema than the COER-verapamil group (P.001). However, the COER-verapamil group experienced more constipation (15% v 8%) (P.016). In a follow-up substudy, data from a 71-symptom checklist that patients completed showed that patients receiving COER-verapamil reported significantly less distress (P.05) than those who received nifedipine GITS. 13 These findings may have implications regarding patient adherence to long-term therapy. CLINICAL IMPLICATIONS The primary differences between the two treatment groups were the effects on heart rate and rate-pressure product. COER-verapamil reduced both these hemodynamic parameters during the early morning hours when heart rate and BP typically rise and when the incidence of cardiovascular events peaks (Figure 5). 1 4,8 These statistically significant reductions are clinically important, because several studies have shown that cardiovascular morbidity and mortality increase with increasing heart rate. 8,14 It follows that a calcium antagonist that lowers heart rate may provide advantages to patients at risk for cardiovascular complications. Although the pathophysiology and pathogenesis of myocardial ischemia have not been fully elucidated, decreased myocardial oxygen supply concurrent with increased oxygen demand appears to be an important trigger, especially in the early morning hours. In a study conducted in 50 patients with coronary artery disease and exercise-induced ST-segment depression, ambulatory electrocardiogram monitoring for ST-segment shift during normal activities revealed that most episodes of ischemia correlated with significant in- FIGURE 5. Circadian variation in various cardiovascular events (based on data from Muller et al, 1 Muller et al, 2 and Rocco et al 4 ).
5 54S WHITE AJH FEBRUARY 1999 VOL. 12, NO. 2, PART 2 creases in heart rate. 9 The patients who experienced ischemia during daily activities underwent stress testing, which demonstrated earlier onset of ST-segment depression occurring at a lower heart rate and ratepressure product than those without ischemia. Interestingly, ST-segment depression occurred in patients who had a relatively high ischemic threshold during exercise (when heart rate was high). Deedwania and Nelson provided insight regarding the relation between rate-pressure product and silent ischemia by performing simultaneous ambulatory BP and Holter monitoring in men with silent coronary artery disease. 5 The authors found that a majority of the ischemic events in their study (85 of 92) were silent and followed a circadian pattern. Nearly two-thirds of these events (61%) were preceded by an increase in heart rate of at least 5 beats/min (P.001). Systolic BP increased an average of 10 mm Hg within 6 min before ST-segment depression in 73% of the silent ischemic events (P.001). Thus, the statistically significant rise in both heart rate and systolic BP indicates that myocardial oxygen demand, represented by the rate-pressure product, may play a role in the development of silent myocardial ischemia. In the current study, the reductions in heart rate and rate-pressure product appear to be associated with the release of COER-verapamil and its onset of activity, which is delayed for several hours after bedtime dosing. Drug serum concentrations peak concurrently with peak incidence of cardiovascular events, and then wane during the day until bedtime, when another dose is taken. The modest but steady reduction in rate-pressure product in patients receiving nifedipine GITS is reflective of the homeostatic delivery system, which provides a constant drug concentration. Although the direct role of heart rate and BP in the pathogenesis of myocardial ischemia remains unknown, it is recognized that a rapid change in heart rate and BP during the early morning hours may trigger myocardial ischemia or infarction. 8 Both COER-verapamil and nifedipine GITS decreased the rate of rise (slope) of BP. However, COER-verapamil significantly decreased the rate of rise of heart rate compared with nifedipine GITS. This finding appears to be dose-related. 15 Nifedipine GITS induced an 11-mm Hg reduction in systolic BP during sleep, whereas the decrease obtained with COER-verapamil was 6 mm Hg. This, in fact, may not be a benefit of nifedipine GITS therapy. Some authors have suggested that excessive reduction in systolic BP, especially in elderly patients, may lead to induction of cerebrovascular events. 16 Thus, COERverapamil may be safer because it provides a more constant, intermediate level of systolic BP. Epidemiologic studies indicate the importance of heart rate in the genesis of cardiovascular events. The circadian pattern of hemodynamic parameters including heart rate and rate-pressure product demonstrate a potentially important role in predicting cardiovascular risk. To test the hypothesis that chronotherapy may reduce the risk for cardiovascular events, a large interventional multicenter study (Controlled Onset Verapamil Investigation of Cardiovascular Endpoints [CONVINCE]) is currently under way to assess the effects of chronotherapy on specific cardiovascular endpoints, as well as circadian variations of morbid events, mortality, and possible triggers of these events. 17 REFERENCES 1. Muller JE, Stone PH, Turi ZG, et al: The MILIS Study Group: circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985;313: Muller JE, Ludmer PL, Willich SN, et al: Circadian variation in the frequency of sudden cardiac death. Circulation 1987;75: Quyyumi AA, Panza JA, Diodati JG, et al: Circadian variation in ischemic threshold. A mechanism underlying the circadian variation in ischemic events. Circulation 1992;86: Rocco M, Campbell BJ, Cook NE, et al: Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation 1987;75: Deedwania PC, Nelson JR: Pathophysiology of silent myocardial ischemia during daily life. Hemodynamic evaluation by simultaneous electrocardiographic and blood pressure monitoring. Circulation 1990;82: Wilhelmsen L, Berglund G, Elmfeldt D, et al: The multifactor primary prevention trial in Göteborg, Sweden. Eur Heart J 1986;7: Kannel WB, Wilson P, Blair SN: Epidemiological assessment of the role of physical activity and fitness in development of cardiovascular disease. Am Heart J 1985;109: Palatini P, Julius S: Heart rate and the cardiovascular risk. J Hypertens 1997;15: Hinderliter A, Miller P, Bragdon E, et al: Myocardial ischemia during daily activities: the importance of increased myocardial oxygen demand. J Am Coll Cardiol 1991;18: Cheitlin MD, Sokolow M, McIlroy MB: Anatomy & physiology of the circulatory system, in Clinical Cardiology. Appleton & Lange, Norwalk, Connecticut, 1993, pp White WB, Black HR, Weber MA, et al: Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. Am J Cardiol 1998;81: Filho AJP, Mansoor GA, White WB: Effects of actual versus arbitrary awake and sleep times on analyses of 24-h blood pressure. Am J Hypertens 1995;8:
6 AJH FEBRUARY 1999 VOL. 12, NO. 2, PART 2 HR, BP, AND CARDIOVASCULAR RISK 55S 13. William GH, Anderson RB, Hollenberg NK, et al: Symptoms and the distress they cause during antihypertensive therapy: comparison of calcium channel blockade with nifedipine GITS and COER-verapamil (abst). Am J Hypertens 1997;10:84A. 14. Gillman MW, Kannel WB, Belanger A, D Agostino RB: Influence of heart rate on mortality among patients with hypertension: the Framingham study. Am Heart J 1993;125: White WB: Circadian variation of blood pressure: clinical relevance and implications for cardiovascular chronotherapeutics. Blood Press Monit 1997;2: Kario K, Matsuo T, Kobayashi H, Imiya M, et al: Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients: advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996;27: Black HR, Elliott WJ, Neaton JD, et al: Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial. Controlled Clin Trials 1998;19:
AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK. Michael Smolensky, Ph.D. The University of Texas Austin & Houston
AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK Michael Smolensky, Ph.D. The University of Texas Austin & Houston Disclosures Partner: Circadian Ambulatory Diagnostics Consultant: Spot On Sciences
More informationANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION*
Progress in Clinical Medicine 1 ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Keishi ABE** Asian Med. J. 44(2): 83 90, 2001 Abstract: J-MUBA was a large-scale clinical
More informationThe hypertensive effects of the renin-angiotensin
Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point
More informationAJH 1999;12: Downloaded from by guest on 15 December 2018
AJH 1999;12:806 814 Differential Effects of Morning and Evening Dosing of Nisoldipine ER on Circadian Blood Pressure and Heart Rate William B. White, George A. Mansoor, Thomas G. Pickering, Donald G. Vidt,
More informationScreening for Asymptomatic Coronary Artery Disease: When, How, and Why?
Screening for Asymptomatic Coronary Artery Disease: When, How, and Why? Joseph S. Terlato, MD FACC Clinical Assistant Professor, Brown Medical School Coastal Medical Definition The presence of objective
More informationIncreased heart rate as a risk factor for cardiovascular disease
European Heart Journal Supplements (23) 5 (Supplement G), G3 G9 Increased heart rate as a risk factor for cardiovascular disease Department of Cardiology, VA Medical Center, West Los Angeles, and Department
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationBlood Pressure Variability and Its Management in Hypertensive Patients
Korean J Fam Med. 2012;33:330-335 http://dx.doi.org/10.4082/kjfm.2012.33.6.330 Blood Pressure Variability and Its Management in Hypertensive Patients Review Hee-Jeong Choi* Department of Family Medicine,
More informationCalculation of Trough-to-Peak Ratio in the Research Unit Setting
A]H 1996; 9:71S-75S Calculation of Trough-to-Peak Ratio in the Research Unit Setting Advantages and Disadvantages Henry L. Elliott and Peter A. Meredith The trough-to-peak ratio for the response to an
More informationInternational Journal of Research and Review E-ISSN: ; P-ISSN:
International Journal of Research and Review www.ijrrjournal.com E-ISSN: 2349-9788; P-ISSN: 2454-2237 Short Communication Rate Pressure Product in Diabetic Cardiac Autonomic Neuropathy at Rest and Under
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationMyocardial ischaemia and angina in the early post-infarction period: a comparison with patients
438 Department of Cardiology, London Chest Hospital B Marchant R Stevenson S Vaishnav A D Timmis Department of Cardiology, Newham General Hospital, London K Ranjadayalan Correspondence to: Dr Bradley Marchant,
More informationBRIEF COMMUNICATIONS. KEY WORDS: Ambulatory blood pressure monitoring, placebo effect, antihypertensive drug trials.
AJH 1995; 8:311-315 BRIEF COMMUNICATIONS Lack of Placebo Effect on Ambulatory Blood Pressure Giuseppe Mancia, Stefano Omboni, Gianfranco Parati, Antonella Ravogli, Alessandra Villani, and Alberto Zanchetti
More informationComparison of arbitrary definitions of circadian time periods with those determined by wrist actigraphy in analysis of ABPM data
Journal of Human Hypertension (1999) 13, 449 453 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Comparison of arbitrary definitions of
More informationAngiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with Arterial Hypertension*
The Journal of International Medical Research 2005; 33 (Suppl 1): 21A 29A Angiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with
More informationPathophysiology of Silent Myocardial
1296 Pathophysiology of Silent Myocardial Ischemia During Daily Life Hemodynamic Evaluation by Simultaneous Electrocardiographic and Blood Pressure Monitoring Prakash C. Deedwania, MD, and John R. Nelson,
More informationHypertension represents one of the most
AJH 1998;11:1376 1380 Changes in Blood Pressure and Heart Rate Variability During Dental Surgery Kiyoshi Matsumura, Keiko Miura, Yutaka Takata, Hideo Kurokawa, Minoru Kajiyama, Isao Abe, and Masatoshi
More informationPrognostic significance of blood pressure measured on rising
(2001) 15, 413 417 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured on rising P Gosse, C Cipriano,
More informationSemilogarithmic relation between rest heart rate and life expectancy
The importance of heart rate in heart failure Karl Swedberg Professor of Medicine Department t of emergency and cardiovascular medicine i Sahlgrenska Academy University of Gothenburg, Sweden karl.swedberg@gu.se
More informationEffects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris
Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments
More informationfunction in patients with ischaemic heart disease
Br. J. clin. Pharmac. (1986), 22, 319S-324S Calcium antagonist treatment and its effects on left ventricular function in patients with ischaemic heart disease E. A. RODRIGUES, I. M. AL-KHAWAJA, A. LAHIRI
More informationEffect of intravenous atropine on treadmill stress test results in patients with poor exercise capacity or chronotropic incompetence ABSTRACT
Effect of intravenous atropine on treadmill stress test results in patients with poor exercise capacity or chronotropic incompetence Samad Ghaffari, MD, Bahram Sohrabi, MD. ABSTRACT Objective: Exercise
More informationHeart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United
Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United States, totaling about 750,000 individuals annually
More informationManagement of the coronary patient in Roberto Ferrari
Management of the coronary patient in 2011 Roberto Ferrari What is new in treatment of stable CAD? In the era of interventional cardiology, is chronic stable angina a rare disease? Stable angina pectoris
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationInitial Medical and Surgical Management of Unstable Angina Pectoris
Clin. Cardiol. 2. 311-316 (I979) G. Witzstrock Publishing House. Inc. Editorial Initial Medical and Surgical Management of Unstable Angina Pectoris Introduction The purpose of this report is to review
More informationTrials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1
Appendix 5 (as supplied by the authors): Published trials on the effect of ivabradine on outcomes including mortality in patients with different cardiovascular diseases Trials Enrolled subjects Findings
More informationAbody of evidence demonstrates that alcohol
BRIEF COMMUNICATIONS AJH 1998;11:230 234 The Effects of Alcohol Consumption on Ambulatory Blood Pressure and Target Organs in Subjects With Borderline to Mild Hypertension Olga Vriz, Diana Piccolo, Enrico
More informationOverview of the outcome trials in older patients with isolated systolic hypertension
Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated
More informationPROFESSOR OF MEDICINE
PRINCIPAL INVESTIGATOR: WHITE, WILLIAM B BIOGRAPHICAL SKETCH Provide the following information for the key personnel and consultants and collaborators. Begin with the principal investigator/program director.
More informationDIURNAL VARIATIONS IN BLOOD PRESSURE AND THEIR RELATION WITH CAROTID ARTERY INTIMA-MEDIA THICKENING
DIURNAL VARIATIONS IN BLOOD PRESSURE AND THEIR RELATION WITH CAROTID ARTERY INTIMA-MEDIA THICKENING Sh Narooei (1), B Soroor (2), F Zaker (3) Abstract INTRODUCTION: Hypertension is a very common cardiovascular
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationOSA and cardiovascular disease what is the evidence? Mohan Edupuganti, MD, FACC. Baptist Health Cardiology. Disclosures: None
OSA and cardiovascular disease what is the evidence? Mohan Edupuganti, MD, FACC. Baptist Health Cardiology. Disclosures: None 1 OSA basics Affects 20-30% of males and 10-15% of females in North America
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationPrognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice
(2005) 19, 801 807 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured in the office, at home and
More informationCentral haemodynamics during spontaneous angina pectoris
British Heart Journal, I974, 36, I0-I09I Central haemodynamics during spontaneous angina pectoris From the Department of Clinical Physiology, Malmo General Hospital, S-214 OI Malmo, Sweden. Central pressures
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationDeclaration of conflict of interest. None to declare
Declaration of conflict of interest None to declare Risk management of coronary artery disease Arrhythmias and diabetes Hercules Mavrakis Cardiology Department Heraklion University Hospital Crete, Greece
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationCARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD, for the CARES Investigators Calhoun Cardiology Center University
More informationRanolazine: An Update
Ranolazine: An Update J. Dawn Abbott, M.D., F.A.C.C., F.S.C.A.I. Director, Interventional Cardiology Fellowship Associate Professor of Medicine Brown Medical School Cardiovascular Institute Outline Ranolazine
More informationAngina Pectoris Dr. Shariq Syed
Angina Pectoris Dr. Syed 1 What is Angina Pectoris (AP)? Commonly known as angina is chest pain often due to ischemia of the heart muscle, Because of obstruction or spasm of the coronary arteries 2 What
More informationRISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine
RISE, FALL AND RESURRECTION OF RENAL DENERVATION Michael A. Weber, MD State University of New York Downstate College of Medicine Michael Weber, Disclosures Research/Trial Commitments and Consulting: Boston
More informationChronopharmacotherapy of Hypertension: Time-dependent effects of treatment on blood pressure
18 Review Article Chronopharmacotherapy of Hypertension: Time-dependent effects of treatment on blood pressure Suresh Rewar 1 *, Bansal BK 1, Singh CJ 2, Sharma AK 2 1 Department of pharmaceutics, Arya
More informationIn the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension
In the name of GOD Animal models of cardiovascular diseases: myocardial infarction & hypertension 44 Presentation outline: Cardiovascular diseases Acute myocardial infarction Animal models for myocardial
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationDr. A. Manjula, No. 7, Doctors Quarters, JLB Road, Next to Shree Guru Residency, Mysore, Karnataka, INDIA.
Original Article In hypertensive patients measurement of left ventricular mass index by echocardiography and its correlation with current electrocardiographic criteria for the diagnosis of left ventricular
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationTime of day for exercise on blood pressure reduction in dipping and nondipping hypertension
(2005) 19, 597 605 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE on blood pressure reduction in dipping and nondipping hypertension S Park,
More informationAmbulatory Care Conference
Ambulatory Care Conference David Stultz, MD August 28, 2002 Case Presentation 50 year old white female presents to ED with substernal chest pain. Pain started while driving, is left substernal in location
More informationData Alert #2... Bi o l o g y Work i n g Gro u p. Subject: HOPE: New validation for the importance of tissue ACE inhibition
Vascular Bi o l o g y Work i n g Gro u p c/o Medical Education Consultants, In c. 25 Sy l van Road South, We s t p o rt, CT 06880 Chairman: Carl J. Pepine, MD Professor and Chief Division of Cardiovascular
More informationMorning Hypertension: A Pitfall of Current Hypertensive Management
Review Article Hypertension: A Pitfall of Current Hypertensive Management JMAJ 48(5): 234 240, 2005 Kazuomi Kario* 1 Abstract has recently attracted more attention because of the close relation between
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationPrevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient
Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient The Issue of Primary Prevention of A.Fib. (and Heart Failure) and not the Prevention of Recurrent A.Fib. after Electroconversion
More informationANGINA PECTORIS. angina pectoris is a symptom of myocardial ischemia in the absence of infarction
Pharmacology Ezra Levy, Pharm.D. ANGINA PECTORIS A. Definition angina pectoris is a symptom of myocardial ischemia in the absence of infarction angina usually implies severe chest pain or discomfort during
More informationNightmares, sleep and cardiac symptoms in the elderly
ORIGINAL ARTICLE Nightmares, sleep and cardiac symptoms in the elderly R. Asplund Family Medicine Stockholm, Karolinska Institute, Research and Development Unit (Jämtland County Council), Sweden, tel.:
More informationRisk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium
Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from
More informationCLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS
CLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS Guideline Title Clinical Investigation of Anti-Anginal Medicinal Products in Stable Angina Pectoris Legislative basis
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationNew Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD
New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD Professor of Medicine, Cell Biology, Radiology and Surgery Director, The Howard Gilman Institute for Heart Valve Disease and the Schiavone
More informationDemonstration of Training Effect During Chronic f-adrenergic Blockade in Patients
Demonstration of Training Effect During Chronic f-adrenergic Blockade in Patients with Coronary Artery Disease CRAIG M. PRATT, M.D., DAVID E. WELTON, M.D., WILLIAM G. SQUIRES, JR., PH.D., TIM E. KIRBY,
More informationHypertensives Emergency and Urgency
Hypertensives Emergency and Urgency Budi Yuli Setianto Cardiology Divisision Department of Internal Medicine Faculty of Medicine UGM Sardjito Hospital Yogyakarta Background USA: Hypertension is 30% of
More informationChapter-V. Summary, Conclusions and Recommendations
Summary, Conclusions and Recommendations INTRODUCTION The work included in this thesis entitled, Circadian heart rate and blood pressure variability in apparently healthy subjects using ABPM has been divided
More informationChronobiologic Aspects of Heart Rate Variability
Chronobiologic Aspects of Heart Rate Variability Frank A.J.L. Scheer, Ph.D. Medical Chronobiology Program, Division of Sleep Medicine Brigham and Women s Hospital and Harvard Medical School Boston, MA,
More informationAssessing Blood Pressure for Clinical Research: Pearls & Pitfalls
Assessing Blood Pressure for Clinical Research: Pearls & Pitfalls Anthony J. Viera, MD, MPH, FAHA Department of Family Medicine Hypertension Research Program UNC School of Medicine Objectives Review limitations
More informationChapter (9) Calcium Antagonists
Chapter (9) Calcium Antagonists (CALCIUM CHANNEL BLOCKERS) Classification Mechanism of Anti-ischemic Actions Indications Drug Interaction with Verapamil Contraindications Adverse Effects Treatment of Drug
More informationDiagnostic and Prognostic Value of Holter-Detected ST-Segment Deviation in Unselected Patients With Chest Pain Referred for Coronary Angiography*
Diagnostic and Prognostic Value of Holter-Detected ST-Segment Deviation in Unselected Patients With Chest Pain Referred for Coronary Angiography* A Long-term Follow-up Analysis Chandra K. Nair, MD, FCCP;
More informationThe Evolution To Treatment Of Hypertension With Advanced Formulation
The Evolution To Treatment Of Hypertension With Advanced Formulation Dr. Donald Ang MBChB (UK) FRCP (Edin) MD (UK) CCST Cardiology (UK) FESC (Europe) Consultant Cardiologist Island Hospital Penang High
More informationCandesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients
1/5 This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
More informationInappropriate Physician Habits in Prescribing Oral Nifedipine Capsules in Hospitalized Patients
A]H 1996;9:1035-2039 Inappropriate Physician Habits in Prescribing Oral Nifedipine Capsules in Hospitalized Patients Faiz Rehman, George A. Mansoor, and William B. White Despite the absence of an approved
More informationAdvances in the Monitoring & Treatment of Heart Failure
Advances in the Monitoring & Treatment of Heart Failure Darrell J. Solet, MD - Cardiologist & Medical Director - Cardiovascular Institute of the South of Morgan City, Louisiana - Clinical Assistant Professor
More informationMany observational studies evaluating the changing pattern
Effect of Aging on the Prognostic Significance of Ambulatory Systolic, Diastolic, and Pulse Pressure in Essential Hypertension Rajdeep S. Khattar, BM, MRCP; John D. Swales, MA, MD, FRCP; Caroline Dore,
More informationPROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE
Press Release Issued on behalf of Servier Date: June 6, 2012 PROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE The new ESC guidelines for the diagnosis and
More informationLarge therapeutic studies in elderly patients with hypertension
(2002) 16 (Suppl 1), S38 S43 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Large therapeutic studies in elderly patients with hypertension Centro Clinico Profesional
More informationRegression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol
Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study Peter M. Okin, MD; Richard B. Devereux,
More informationHow well do office and exercise blood pressures predict sustained hypertension? A Dundee Step Test Study
(2000) 14, 429 433 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE How well do office and exercise blood pressures predict sustained hypertension?
More informationDisclosures (2013 to the present)
What level and types of CV safety data acquisition should be considered to sufficiently characterize a drug s benefit/risk assessment by the end of Phase 3 development? Cardiac Safety Research Consortium
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationTHE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease
THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS 1. Cardiovascular Disease Cardiovascular disease is considered to have developed if there was a definite manifestation
More informationβ adrenergic blockade, a renal perspective Prof S O McLigeyo
β adrenergic blockade, a renal perspective Prof S O McLigeyo Carvedilol Third generation β blocker (both β 1 and β 2 ) Possesses α 1 adrenergic blocking properties. β: α blocking ratio 7:1 to 3:1 Antioxidant
More informationAcute Myocardial Infarction: Difference in the Treatment between Men and Women
Quality Assurance in Hcahh Can, Vol. 5, No. 3, pp. 261-265,1993 Printed in Great Britain 1040-6166/93 $6.00 + 0.00 1993 Pergamon Press Ltd Acute Myocardial Infarction: Difference in the Treatment between
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationAdverse effects of caffeine after a single dose and after repeated doses consumed within a day
Adverse effects of caffeine after a single dose and after repeated doses consumed within a day Anders Sjödin Copenhagen University (Denmark) Chair of EFSA s WG on caffeine EFSA STAKEHOLDERS MEETING ON
More informationHypertension is a common disease in our
AJH 2000;13:1161 1167 Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on or Trefor O. Morgan, Adrianne Anderson, and Denise Bertram Arthritis and
More informationAmbulatory Blood Pressure Monitoring Clinical Practice Recommendations
Acta Medica Marisiensis 2016;62(3):350-355 DOI: 10.1515/amma-2016-0038 UPDATE Ambulatory Blood Pressure Monitoring Clinical Practice Recommendations Mako Katalin *, Ureche Corina, Jeremias Zsuzsanna University
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationManagement of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University
Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:
More informationRecent Advances in Ambulatory Blood Pressure
C H A P T E R 150 Recent Advances in Ambulatory Blood Pressure Ashok L Kirpalani, Dilip A Kirpalani The understanding of Hypertension has evolved over the last century. A single mercury manometer reading
More informationListing Form: Heart or Cardiovascular Impairments. Medical Provider:
Listing Form: Heart or Cardiovascular Impairments Medical Provider: Printed Name Signature Patient Name: Patient DOB: Patient SS#: Date: Dear Provider: Please indicate whether your patient s condition
More informationPrediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring
Prediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring Yu-Zhen ZHANG, M.D.,* Shi-Wen WANG, M.D.,* Da-Yi Hu, M.D.,**
More informationA Comparative Study on the Effect of Ranolazine and Ivabradine on High Sensitivity C - reactive protein In Cardiac Patients
Human Journals Mini Review March 2017 Vol.:8, Issue: 4 All rights are reserved by Prof. Dr. Mathew George et al. A Comparative Study on the Effect of Ranolazine and Ivabradine on High Sensitivity C - reactive
More informationAcute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
More informationJournal of the American College of Cardiology Vol. 40, No. 1, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 40, No. 1, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01923-X
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More information